AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8301432 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual chest percussion
Number of subjects: 51
Study 8301432 — intervention group
Group type: COMPARATOR
Intervention: Mechanical chest percussion
Number of subjects: 51
Study 2500040 — intervention group
Group type: EXPERIMENTAL
Intervention: IV nitroglycerin 1 microgram.kg‐1.min‐1 (NTG group)
Number of subjects: 20
Study 2500040 — intervention group
Group type: COMPARATOR
Intervention: IV saline (control group)
Number of subjects: 20
Study 4583184 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 150 mg daily
Number of subjects: 35
Study 4583184 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 1,200 mg daily
Number of subjects: 35
Study 31957508 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 0
Study 31957508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30775783 — intervention group
Group type: EXPERIMENTAL
Intervention: Panelist‐Articulated‐2‐Alternative Forced Choice (PA‐2‐AFC)
Number of subjects: 61
Study 30775783 — intervention group
Group type: EXPERIMENTAL
Intervention: Triangle testing methodologies
Number of subjects: 61
Study 30775783 — intervention group
Group type: EXPERIMENTAL
Intervention: Triangle with partial presentation
Number of subjects: 61
Study 30775783 — intervention group
Group type: EXPERIMENTAL
Intervention: Duo-trio
Number of subjects: 61
Study 30775783 — intervention group
Group type: EXPERIMENTAL
Intervention: Duo-trio with partial presentation
Number of subjects: 61
Study 30775783 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-category rating methods for R-index measure
Number of subjects: 61
Study 30775783 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-different pairwise comparison for R-index measure
Number of subjects: 61
Study 28523355 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg
Number of subjects: 37
Study 28523355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 25299832 — intervention group
Group type: COMPARATOR
Intervention: Normal hearing
Number of subjects: 764
Study 25299832 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral hearing loss
Number of subjects: 764
Study 25299832 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral hearing loss
Number of subjects: 764
Study 23785044 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Number of subjects: 70
Study 23785044 — intervention group
Group type: COMPARATOR
Intervention: Physical exercise
Number of subjects: 70
Study 21784296 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy (BT) protocol consisting of eight weekly sessions
Number of subjects: 24
Study 21784296 — intervention group
Group type: COMPARATOR
Intervention: Minimal attention control (MAC) condition consisting of three sessions and five telephone calls over 8 weeks
Number of subjects: 24
Study 19627350 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health-promotion approach
Number of subjects: 250
Study 19627350 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-strategy and promotion approach
Number of subjects: 250
Study 19627350 — intervention group
Group type: COMPARATOR
Intervention: Reference group (Rauma)
Number of subjects: 250
Study 16883311 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF and GM‐CSF (5 x 2 microg/kg/day)
Number of subjects: 120
Study 16883311 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF and GM‐CSF (2.5 x 2 microg/kg/day)
Number of subjects: 120
Study 16883311 — intervention group
Group type: COMPARATOR
Intervention: G‐CSF (5 microg/kg/day)
Number of subjects: 120
Study 16883311 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF plus GM‐CSF
Number of subjects: 120
Study 15637216 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus up to 1,375 Kcal [5,755 kJ/d] of nasoenteral tube feedings each night
Number of subjects: 57
Study 15637216 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 57
Study 11556510 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapulpal anaesthesia with lidocaine hydrochloride 2% (Group A)
Number of subjects: 41
Study 11556510 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapulpal anaesthesia with lidocaine hydrochloride 2% with adrenaline 1:100,000 (Group B)
Number of subjects: 41
Study 11556510 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthesia with a mandibular block using prilocaine hydrochloride 3% with felypressin 1:100,000 (Group C)
Number of subjects: 41
Study 9586615 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (250 mg once daily for 7 to 10 days)
Number of subjects: 336
Study 9586615 — intervention group
Group type: COMPARATOR
Intervention: Lomefloxacin (400 mg once daily for 14 days)
Number of subjects: 336
Study 8139604 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide mesylate
Number of subjects: 376
Study 8139604 — intervention group
Group type: COMPARATOR
Intervention: Sinemet (levodopa)
Number of subjects: 376
Study 2463565 — intervention group
Group type: EXPERIMENTAL
Intervention: DVI/DDD pacing
Number of subjects: 23
Study 2463565 — intervention group
Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 23
Study 2463565 — intervention group
Group type: EXPERIMENTAL
Intervention: DVI/DDD pacing (Group A)
Number of subjects: 23
Study 2463565 — intervention group
Group type: COMPARATOR
Intervention: VVI pacing (Group B)
Number of subjects: 23
Study 2463565 — intervention group
Group type: COMPARATOR
Intervention: Carotid sinus massage during VVI mode
Number of subjects: 23
Study 2463565 — intervention group
Group type: COMPARATOR
Intervention: Carotid sinus massage during DVI mode
Number of subjects: 23
Study 31358482 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit prior to hospital ICU admission
Number of subjects: 38
Study 31358482 — intervention group
Group type: COMPARATOR
Intervention: No visit prior to hospital ICU admission (Control)
Number of subjects: 38
Study 27979046 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Management (SM) training
Number of subjects: 134
Study 27979046 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (EX)
Number of subjects: 134
Study 27979046 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 134
Study 26028058 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein (HP) breakfast (350 kcal, 35 g protein)
Number of subjects: 28
Study 24219183 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime anhedonia
Number of subjects: 1469
Study 24219183 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime depressed mood
Number of subjects: 1469
Study 24219183 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime anhedonia (after controlling for depressed mood)
Number of subjects: 1469
Study 24219183 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime depressed mood (after controlling for anhedonia)
Number of subjects: 1469
Study 20625950 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless THA
Number of subjects: 250
Study 20625950 — intervention group
Group type: COMPARATOR
Intervention: Cemented THA
Number of subjects: 250
Study 19283884 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoyl glucuronide (RAG) administered orally to Group II (n 42), blood collected 4 hours after dosing.
Number of subjects: 61
Study 19283884 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group I, n 19) not dosed with RAG.
Number of subjects: 61
Study 17719942 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic supplement
Number of subjects: 97
Study 17719942 — intervention group
Group type: COMPARATOR
Intervention: Control (maltodextrin)
Number of subjects: 97
Study 17719942 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic supplement (with calcium intake > or = 700 mg/d)
Number of subjects: 97
Study 15030839 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia (lidocaine hydrochloride 2% gel)
Number of subjects: 76
Study 15030839 — intervention group
Group type: COMPARATOR
Intervention: Regional anesthesia (peribulbar or retrobulbar injection of lignocaine 2%)
Number of subjects: 76
Study 11578789 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive addition lenses (PALs) - Varilux Comfort with a +2.00 D addition
Number of subjects: 469
Study 11578789 — intervention group
Group type: COMPARATOR
Intervention: Conventional single vision lenses (SVLs)
Number of subjects: 469
Study 9390011 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 0.03 mg/kg
Number of subjects: 11
Study 9390011 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 11
Study 9390011 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH)
Number of subjects: 11
Study 7886391 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (16 mg, orally)
Number of subjects: 9
Study 7886391 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral)
Number of subjects: 9
Study 7886391 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (intraluminal infusion)
Number of subjects: 9
Study 7886391 — intervention group
Group type: COMPARATOR
Intervention: Loperamide (intraluminal infusion)
Number of subjects: 9
Study 3279743 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (IS-5-MN) 20 mg 3 times a day or 50 mg in a sustained-release tablet
Number of subjects: 20
Study 3279743 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 20 mg in a sustained-release tablet 3 times a day
Number of subjects: 20
Study 29233569 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal + CACB
Number of subjects: 145
Study 29233569 — intervention group
Group type: EXPERIMENTAL
Intervention: General + CACB
Number of subjects: 145
Study 29233569 — intervention group
Group type: COMPARATOR
Intervention: CSE
Number of subjects: 145
Study 27477951 — intervention group
Group type: EXPERIMENTAL
Intervention: Hb‐PTFE grafts
Number of subjects: 569
Study 27477951 — intervention group
Group type: COMPARATOR
Intervention: Standard PTFE grafts
Number of subjects: 569
Study 24996519 — intervention group
Group type: EXPERIMENTAL
Intervention: Lessons with a mirror (mirror-group)
Number of subjects: 64
Study 24996519 — intervention group
Group type: COMPARATOR
Intervention: Lessons without a mirror (non-mirror group)
Number of subjects: 64
Study 22649287 — intervention group
Group type: EXPERIMENTAL
Intervention: Project PATHS program
Number of subjects: 2850
Study 22649287 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Project PATHS participation)
Number of subjects: 2850
Study 20220206 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline intake 300 mg/d
Number of subjects: 60
Study 20220206 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline intake 550 mg/d
Number of subjects: 60
Study 20220206 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline intake 1100 mg/d
Number of subjects: 60
Study 20220206 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline intake 2200 mg/d
Number of subjects: 60
Study 20220206 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline intake 300 mg/d and 550 mg/d
Number of subjects: 60
Study 20220206 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline intake (varied levels)
Number of subjects: 60
Study 20220206 — intervention group
Group type: COMPARATOR
Intervention: Choline intake (all levels)
Number of subjects: 60
Study 18503895 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA) alone
Number of subjects: 197
Study 18503895 — intervention group
Group type: EXPERIMENTAL
Intervention: PTA followed by stent-graft placement (expanded polytetrafluoroethylene/nitinol self-expanding stent-graft)
Number of subjects: 197
Study 15670103 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking during pregnancy
Number of subjects: 274
Study 14723030 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive surgery
Number of subjects: 0
Study 14723030 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 0
Study 10553933 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast-derived vaccine
Number of subjects: 0
Study 10553933 — intervention group
Group type: COMPARATOR
Intervention: Plasma-derived vaccine
Number of subjects: 0
Study 8572340 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/Alfentanil combination
Number of subjects: 10
Study 8572340 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil alone
Number of subjects: 10
Study 8572340 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 10
Study 1441044 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg orally twice daily for 10-21 days)
Number of subjects: 72
Study 1441044 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg orally every 12 hours for 14-21 days)
Number of subjects: 72
Study 1441044 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 72
Study 1441044 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin and Ciprofloxacin
Number of subjects: 72
Study 3931142 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan-free amino acid mixture
Number of subjects: 3
Study 3931142 — intervention group
Group type: COMPARATOR
Intervention: Balanced amino acid mixture
Number of subjects: 3
Study 3931142 — intervention group
Group type: COMPARATOR
Intervention: Excess tryptophan amino acid mixture
Number of subjects: 3
Study 31690824 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine
Number of subjects: 46
Study 31690824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 30011900 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback system training (two protocols with different temporal lengths)
Number of subjects: 6
Study 24568894 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5mg/d)
Number of subjects: 6374
Study 24568894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6374
Study 22782060 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% titanium tetrafluoride (TiF4) applied once with sodium monofluorophosphate (MFP) dentifrice for four weeks
Number of subjects: 8
Study 22782060 — intervention group
Group type: COMPARATOR
Intervention: sodium monofluorophosphate (MFP) dentifrice only
Number of subjects: 8
Study 21143904 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose rate (LDR) Ra‐226 brachytherapy (n = 4; median 70Gy)
Number of subjects: 21
Study 21143904 — intervention group
Group type: EXPERIMENTAL
Intervention: Ir‐192 brachytherapy (n = 12; 70Gy)
Number of subjects: 21
Study 21143904 — intervention group
Group type: EXPERIMENTAL
Intervention: Au‐198 brachytherapy (n = 1)
Number of subjects: 21
Study 21143904 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose rate (HDR) Ir‐192 brachytherapy (n = 4; 60 Gy)
Number of subjects: 21
Study 21143904 — intervention group
Group type: EXPERIMENTAL
Intervention: External radiotherapy (8 patients, median 30 Gy)
Number of subjects: 21
Study 21143904 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 21
Study 21143904 — intervention group
Group type: EXPERIMENTAL
Intervention: Cause-specific survival
Number of subjects: 21
Study 21143904 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional control
Number of subjects: 21
Study 17285183 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BTX)
Number of subjects: 0
Study 17285183 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 16250032 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b plus ribavirin 15 mg/kg/d
Number of subjects: 118
Study 12015628 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult air divers
Number of subjects: 173
Study 12015628 — intervention group
Group type: COMPARATOR
Intervention: Young recreational divers
Number of subjects: 173
Study 10188752 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% of one repetition maximum (1RM)
Number of subjects: 84
Study 10188752 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% of one repetition maximum (1RM)
Number of subjects: 84
Study 10188752 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% and 80% of one repetition maximum (1RM)
Number of subjects: 84
Study 10188752 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 84
Study 7473483 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip Ability Test (GAT)
Number of subjects: 24
Study 2531153 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin (400 micrograms daily)
Number of subjects: 18
Study 2531153 — intervention group
Group type: COMPARATOR
Intervention: Danazol (600 mg daily)
Number of subjects: 18
Study 4921092 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a computer for clerical work in the trial
Number of subjects: 0
Study 4921092 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 30488303 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-guided high-dose-rate (HDR) brachytherapy (iBT)
Number of subjects: 77
Study 30488303 — intervention group
Group type: COMPARATOR
Intervention: Conventional transarterial chemoembolization (cTACE)
Number of subjects: 77
Study 28626050 — intervention group
Group type: EXPERIMENTAL
Intervention: Global GM volume
Number of subjects: 248
Study 28626050 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower GM volumes in left fronto‐temporo‐insular cortex
Number of subjects: 248
Study 28626050 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower GM volumes in right temporo‐insular cortex and basal ganglia
Number of subjects: 248
Study 24997614 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Training (CT, n=9)
Number of subjects: 19
Study 24997614 — intervention group
Group type: COMPARATOR
Intervention: Aerobic Training (AT, n=10)
Number of subjects: 19
Study 23407006 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategy including patient-facing kiosks, continuous data feedback, clinical champions, education, social marketing, and evidence-based quality improvement teams.
Number of subjects: 571
Study 23407006 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategy
Number of subjects: 571
Study 23407006 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 571
Study 21415812 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar disc arthroplasty (investigational group)
Number of subjects: 577
Study 21415812 — intervention group
Group type: COMPARATOR
Intervention: Anterior lumbar interbody fusion (control group)
Number of subjects: 577
Study 19356442 — intervention group
Group type: EXPERIMENTAL
Intervention: Regadenoson
Number of subjects: 2015
Study 19356442 — intervention group
Group type: COMPARATOR
Intervention: Adenosine
Number of subjects: 2015
Study 16505085 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity active exercise (ACT)
Number of subjects: 23
Study 16505085 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast water therapy (CWT)
Number of subjects: 23
Study 16505085 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression garment (GAR)
Number of subjects: 23
Study 16505085 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery (PAS)
Number of subjects: 23
Study 12900682 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3; 0.3 g.kg−1)
Number of subjects: 8
Study 12900682 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (NaCl; 0.045 g.kg−1)
Number of subjects: 8
Study 11011709 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous bilateral PRK
Number of subjects: 52
Study 11011709 — intervention group
Group type: COMPARATOR
Intervention: Sequential bilateral PRK
Number of subjects: 52
Study 9348450 — intervention group
Group type: EXPERIMENTAL
Intervention: RGP scleral lenses with Dk 32 and thicknesses of 0.15, 0.30, 0.60, and 1.20 mm
Number of subjects: 4
Study 9348450 — intervention group
Group type: EXPERIMENTAL
Intervention: RGP scleral lenses with Dk 59 and thicknesses of 0.15, 0.30, 0.60, and 1.20 mm
Number of subjects: 4
Study 9348450 — intervention group
Group type: EXPERIMENTAL
Intervention: RGP scleral lenses with Dk 115 and thicknesses of 0.15, 0.30, 0.60, and 1.20 mm
Number of subjects: 4
Study 8450243 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleoside therapy (zidovudine, 2',3'-dideoxyinosine, or both) for a mean of 20 months
Number of subjects: 36
Study 8450243 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 36
Study 8450243 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleoside therapy
Number of subjects: 36
Study 3739801 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie-counting diet
Number of subjects: 0
Study 3739801 — intervention group
Group type: COMPARATOR
Intervention: Exchange system diet
Number of subjects: 0
Study 30261350 — intervention group
Group type: EXPERIMENTAL
Intervention: Elaborative reminiscing intervention
Number of subjects: 88
Study 30261350 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 88
Study 27113376 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (prenatal and postpartum individual nutrition/breastfeeding counseling)
Number of subjects: 533
Study 27113376 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 533
Study 24805282 — intervention group
Group type: EXPERIMENTAL
Intervention: SONO (ultrasound-guided quadruple injection axillary block)
Number of subjects: 60
Study 24805282 — intervention group
Group type: COMPARATOR
Intervention: STIM (nerve stimulation-guided triple injection axillary block)
Number of subjects: 60
Study 24805282 — intervention group
Group type: EXPERIMENTAL
Intervention: SONO
Number of subjects: 60
Study 24805282 — intervention group
Group type: COMPARATOR
Intervention: STIM
Number of subjects: 60
Study 23186567 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% povidone iodine mouthrinse
Number of subjects: 34
Study 23186567 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouthrinse
Number of subjects: 34
Study 23186567 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (sterile saline) solution
Number of subjects: 34
Study 20473257 — intervention group
Group type: COMPARATOR
Intervention: High-dose corticosteroids
Number of subjects: 0
Study 20473257 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose corticosteroids
Number of subjects: 0
Study 20473257 — intervention group
Group type: COMPARATOR
Intervention: Short-duration, high-dose glucocorticoid therapy
Number of subjects: 0